Yiqi-Shengjin Granules Clinical Trial Protocol for Hypertension and Glucose Metabolism

A 111.0 KB study protocol document outlines an 8-week randomized, double-blind, placebo-controlled clinical trial. The trial, registered as ChiCTR2200062453, investigates the effect and safety of Yiqi-Shengjin granules combined with losartan in patients with hypertension and abnormal glucose metabolism. It was authored by Haoyue Shi and last updated on 2026-05-11.

Use Cases

• Analyzing clinical trial design and endpoints based on the described primary and secondary outcome measures.
• Studying the application of traditional Chinese medicine formulations based on the description of Yiqi-Shengjin granules.
• Evaluating safety and efficacy assessment frameworks based on the described 8-week treatment and follow-up schedule.
• Researching cardiovascular disease risk factors based on the described indicators for vascular damage, oxidative stress, and major adverse cardiovascular events (MACE).

Strengths

• The protocol is detailed, describing a randomized, double-blind, placebo-controlled study design with a 1:1 allocation ratio.
• It specifies a concrete 8-week (56-day) treatment period with follow-up visits scheduled every 2 weeks.
• The document is licensed under CC-BY-4.0, allowing for broad reuse and sharing.

Limitations

• The dataset is a 111.0 KB DOC file containing only the study protocol, not the resulting clinical trial data.
• Row count and column-level documentation are unknown, as the actual trial data is not provided.
• The data's freshness should be verified, as the last update date is in the future (2026-05-11).

Provenance

Source

figshare

Collection Method

Designed as a clinical trial protocol.

Time Range

The protocol describes an 8-week treatment period, but the specific execution dates are not provided.

Freshness

Last updated 2026-05-11 05:25:13

Geography

The trial is associated with Beijing Hospital of Traditional Chinese Medicine, suggesting a likely primary location in China.